The stock price of Elite Pharmaceuticals increased despite a net loss in Q2 earnings, indicating that investors are optimistic about the company's future prospects. This optimism is likely due to the strong revenue growth driven by new product launches and strategic acquisitions, which are seen as positive indicators for the company's long-term growth potential.